Xilio Therapeutics (NASDAQ:XLO – Get Rating) and NGM Biopharmaceuticals (NASDAQ:NGM – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings and profitability. Insider and Institutional Ownership 72.3% of Xilio Therapeutics shares […]
Wall Street analysts forecast that NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) will report earnings of ($0.42) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for NGM Biopharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.65). NGM Biopharmaceuticals […]
Analysts expect NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) to report $22.35 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for NGM Biopharmaceuticals’ earnings. The lowest sales estimate is $15.00 million and the highest is $29.69 million. NGM Biopharmaceuticals posted sales of $21.58 million during the same […]
California State Teachers Retirement System trimmed its holdings in shares of NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) by 2.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,375 shares of the company’s stock after selling 1,081 shares during the period. California […]